ERBB2 and neoplasm: Despite differences in drug payloads and readouts (tumor volume, relative tumor volume, inhibitory rate), which call for cautious interpretation of cross-study comparisons, the directional concordance across studies supports our conclusion that active HER2 targeting, particularly when combined with dual-drug delivery, enhances in vivo antitumor efficacy beyond non-targeted nanoformulations.